Detection of ctDNA Predicts Clinical Outcome in BRAFV600 Melanoma
A team of researchers assessed the relationship between BRAFV600-mutant ctDNA in plasma samples and outcomes in patients with BRAFV600 mutation-positive melanoma.
A team of researchers assessed the relationship between BRAFV600-mutant ctDNA in plasma samples and outcomes in patients with BRAFV600 mutation-positive melanoma.
Fecal microbiota transplantation together with anti-programmed cell death protein 1 therapy possibly may alter the gut microbiome and overcome resistance to anti-PD-1 in some patients with melanoma.
Concomitant treatment of common comorbidities of HS, including anxiety and depression, metabolic syndrome, and smoking, may improve treatment outcomes.
Researchers wanted to determine whether histologically confirmed regression was associated with better or worse survival in patients with primary cutaneous melanoma.
The FDA has approved Libtayo for the treatment of patients with locally advanced and metastatic basal cell carcinoma (laBCC) who have previously received a hedgehog pathway inhibitor (HHI) or for whom an HHI is not appropriate
Investigators reviewed the clinical outcomes of patients with metastatic melanoma who electively discontinued PD-1 inhibitor therapy at 1 year.
The differences in incidence, clinical features, genetics, treatment and outcome, in cutaneous melanoma in White vs people of African descent populations is reviewed.
In a new guidance statement from the National Comprehensive Cancer Network, recommendations are presented for COVID-19 vaccination of cancer patients.
Data surrounding the association of UV exposure and risk for cutaneous melanoma in patients with skin of color was assessed.
The American Cancer Society’s annual report approximates the new cancer diagnoses and deaths expected in 2021 and identifies impactful patterns in oncology care.